Article

Boston Scientific sees losses narrow in Q3, despite falling stent sales

Boston Scientific has reported its financial results for the 2008 third quarter, which ended September 30, as well as its guidance for net sales for the fourth quarter of this year.

Government probes FDA actions in Actavis recalls

The House Energy and Commerce Committee is investigating alleged FDA shortcomings to request more information about Actavis recalls, including withdrawal of all products from its Little Falls, N.J. plant.

HORIZONS AMI data will likely lead to wider bivalirudin usage in acute MI

WASHINGTONAfter one year, use of bivalirudin in MI patients, who receive angioplasty, resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding, compared to the standard drug therapy of heparin and glycoprotein IIb/IIIa inhibitors, according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

HORIZONS AMI finds DES more effective, as safe as BMS at one year

WASHINGTONAfter one year, use of a drug-eluting stent (DES) in heart attack patients demonstrated significantly reduced rates of target lesion revascularization and binary angiographic restenosis when compared to the use of a bare metal stent (BMS), according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Physicians at the root of Medicaid cancer screening delinquency

Only about half of Medicaid recipients age 50 and older appear to receive recommendations from their primary care physicians to undergo screening tests for colorectal, breast and cervical cancer, according to a report in the October 13 issue of Archives of Internal Medicine.

FDA OKs Boston Scientific Taxus Liberte after two-year delay

Boston Scientific has received approval from the FDA to market its second-generation Taxus Liberte paclitaxel-eluting coronary stent system.

EMEA addresses radioisotope shortage; appeals to private industry

The European Medicines Agency (EMEA), at the request from the EuropeanCommission, has performed an analysis on the current shortage ofradiopharmaceuticals in the European Union to develop potentialsolutions.

Medtronic, Bos Sci ordered to pay J&J about $1.2B for stent patents

The U.S. District Court in Delaware has awarded Johnson & Johnson (J&J) damages totaling $406.7 million and pre-judgment interest totaling $296 million from Boston Scientific and $521 million from Medtronic, in a case involving a stent patent owned by J&J.

Around the web

U.S. health systems are increasingly leveraging digital health to conduct their operations, but how health systems are using digital health in their strategies can vary widely.

When human counselors are unavailable to provide work-based wellness coaching, robots can substitute—as long as the workers are comfortable with emerging technologies and the machines aren’t overly humanlike.

A vendor that supplies EHR software to public health agencies is partnering with a health-tech startup in the cloud-communications space to equip state and local governments for managing their response to the COVID-19 crisis.